Drug Interactions between olaparib and rucaparib
This report displays the potential drug interactions for the following 2 drugs:
- olaparib
- rucaparib
Interactions between your drugs
olaparib rucaparib
Applies to: olaparib and rucaparib
MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. In a drug interaction study with 57 patients, olaparib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.4- and 2.7-fold, respectively, during coadministration with the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase olaparib Cmax by 1.1-fold and AUC by 2-fold. No data are available for use with other, less potent inhibitors. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.
MANAGEMENT: Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected.
References
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):
Drug and food interactions
olaparib food
Applies to: olaparib
GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of olaparib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In a drug interaction study with 57 patients, olaparib systemic exposure (AUC) was increased approximately 2.7-fold by the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase the AUC of olaparib by 2-fold. The interaction has not been studied with grapefruit juice. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.
MANAGEMENT: Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Parp inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'PARP inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'PARP inhibitors' category:
- olaparib
- rucaparib
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.